In China, both local and foreign clinical trials are accepted for drug approval. However, foreign clinical trial data must meet Chinese regulatory standards. Often, supplementary local trials are required to ensure the drug’s safety and efficacy in the Chinese population, aligning with the National Medical Products Administration (NMPA) guidelines.
